REMINDER: Our user survey closes on Friday, please submit your responses here.
Everyone is saying what a fantastic product this is.
For me it sells itself.
We have only very recently added 40+ now another 20 million insured Americans.
There is no point in assessing performance when prescribing was not straightforward with the drug on the healthcare insurers approved list. It seems to me that they have now reached a critical mass of insurers signed up and the prescriptions should fly from here. Only last week I had a patient with symptomatic anaemia that I would have loved to have prescribed this for, but it is not on our formulary. Colleagues worry that if it gets on the formulary that it will be used indiscriminately. The insurance coverage was always going to be the make or break for success in my opinion. DYOR
The RNS talks about the number of patients signed up to medical insurance companies that have already signed off on accrufer as I understand it.
The 9million IDA patients in America is now 11.8 ml and will keep growing with an aging population.
I can only dream of 54P
Search on Twitter today shows PubMed articles strongly advocating in July and October this year. The educational angle is finally being addressed which is exciting for a product that sells itself even to a cynical medic like me.
Very interesting
So ferric citrate is the only oral competitor mentioned in the table with IV. I see that this is a phosphate binder used in CKD. Does anyone know how it compares with ferric maltol (apart from our CEO of course!)?
Avacta have just started prodoxyrubicin trial AVA6000 on stage 4 oesophageal cancer. Would this be something that angle should get involved in looking at measuring reduced CTCs? The tumour cells secrete an enzyme which splits into active doxyrubicin in the tumour micro environment and has had amazing results in solid tumours in mice
Spoke to Professor of renal medicine with decades of experience with oral and IV iron. He didn’t seem to properly understand that this is not a salt and not asking to be first line.
I absolutely agree with your strategy for switching. In USA Shield have reported the high volume prescribers WANT to prescribe it.
Sadly that doesn’t seem to be the case in the UK, we need tweets from haematology and renal opinion leaders endorsing the plan and survey of support from relevant specialists.
I have prescribed Ferric maltol myself a few times as a GP, I am a little confused why it hasn’t caught on.
I have been doing some unfortunately belated networking and have discovered that it has been considered for heart failure anaemia but considered too expensive.
The London renal clinics also know about it but consider too expensive.
The way hospitals get paid for activity currently might mean that a higher cost for IV iron infusion might be borne by the whole NHS rather than the hospital. A prescription for a drug might just be a cost.
The changes now arriving with local budgets might change this thinking, and I think others have posted US system is better at investing for total rather than isolated cost savings.
I still don’t understand with 90% mark up, they don’t halve the cost and aim for bigger market share.
90 % of not very much...is not very much!